Department of Internal Medicine, Advent Health, Orlando, FL, USA.
Department of Gastroenterology, Cleveland Clinic, Cleveland, OH, USA.
Int J Colorectal Dis. 2019 Apr;34(4):569-580. doi: 10.1007/s00384-019-03269-3. Epub 2019 Mar 11.
Patients with ulcerative colitis and Crohn's colitis have an increased risk of developing dysplasia and colorectal cancer as compared to the general population; surveillance colonoscopy is recommended in this patient population.
This review of the published literature aimed to assess the published evidence.
Detection of dysplasia requires examination of mucosa with targeted biopsies of the visible lesions as well as random biopsies to detect invisible lesions. Newer endoscopic techniques, in particular chromoendoscopy, increase the yield of identifying dysplastic lesions. The surveillance for Colorectal Endoscopic Neoplasia Detection and Management in Inflammatory Bowel Disease Patients International Consensus (SCENIC) guidelines recommends that colonoscopy using chromoendoscopy is the optimal endoscopic surveillance strategy to detect dysplasia. Once dysplastic lesions are discovered on surveillance endoscopic examination, careful and meticulous descriptions of lesions is mandatory to aid in further decision making. Management of dysplastic lesions in inflammatory bowel disease patients depends on endoscopic (morphological) and histologic findings and patient characteristics such as age, general condition of the patient, and patient preferences. Endoscopic mucosal resection, endoscopic submucosal dissection, and surgery are different therapeutic options for colonic dysplastic lesions detected in the setting of inflammatory bowel disease.
In this review, we discuss the various techniques for endoscopic resection of dysplasia in patients with inflammatory bowel disease. Further research is required to determine the optimal approach to diagnosis and management of dysplasia in patients with inflammatory bowel disease.
与普通人群相比,溃疡性结肠炎和克罗恩病患者发生异型增生和结直肠癌的风险增加;建议对此类患者进行结肠镜监测。
本研究对已发表的文献进行了综述,旨在评估已发表的证据。
异型增生的检测需要对可见病变进行靶向活检,并对不可见病变进行随机活检,以检查黏膜。新型内镜技术,特别是 chromoendoscopy,提高了识别异型增生病变的检出率。国际炎症性肠病患者结直肠内镜肿瘤检测和管理共识(SCENIC)指南建议,采用 chromoendoscopy 的结肠镜检查是检测异型增生的最佳内镜监测策略。一旦在监测性内镜检查中发现异型增生病变,必须仔细和细致地描述病变,以帮助进一步决策。炎症性肠病患者异型增生病变的处理取决于内镜(形态学)和组织学发现以及患者特征,如年龄、患者一般状况和患者偏好。内镜黏膜切除术、内镜黏膜下剥离术和手术是治疗炎症性肠病中发现的结肠异型增生病变的不同治疗选择。
在本综述中,我们讨论了用于内镜切除炎症性肠病患者异型增生的各种技术。需要进一步的研究来确定炎症性肠病患者异型增生的诊断和管理的最佳方法。